Investors in 2025 aren’t just backing biotech science—they’re judging execution. CEOs who can’t show scaling signals—operational rhythm, cross-team clarity, and a real scalability narrative—risk burning credibility, not just capital. This memo breaks down the three signals biotech leaders must master to win trust and funding.

If your company still operates the same way it did three years ago, you’re already behind. The pace of change in biotech has never been...